Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They push it down like everything else.... spreading everyone too thin... weakens momentum
I wonder who the referenced vaccine developer is?
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
https://finance.yahoo.com/news/zosano-pharma-announces-successful-formulation-130000245.html
FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano’s microneedle patch system. Zosano’s patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator.
Big Monday morn ahead.. burning shorts.
How do they prevent raising more cash at this point. FDA approval so far away after having to run “healthy volunteer pharmacokinetic study” - trying to submit by end of year. They do not have enough cash to make it through FDA decision - 2nd quarter 2022 at the earliest.
From PR
As of June 30, 2021, cash and cash equivalents were $22.1 million, compared with $35.3 million as of December 31, 2020.
they pay themselves too much more, should be around 0.5
It's not too late to vote to withhold Steve Lo from the Board of Directors. He needs more time to achieve compensation goals set by the BOD.
https://www.sec.gov/Archives/edgar/data/0001587221/000158722121000010/proxy2021.htm#i1f3d117d2c154d89b3521dd5b84f5f23_82
Help Steve and help the Investors.
* * $ZSAN Video Chart 05-27-2021 * *
Link to Video - click here to watch the technical chart video
NICE $ZSAN
So when do you think the NASDAQ is going to toss this trash ticker ZSAN down to the lowly OTC pinks garbage heap.
There better be some good news soon before we go bankrupt....
so Lo just gave a rehash of what we already knew except he did say they have submitted pk protocol to fda and are awaiting feedback so they can then proceed with pk study and resubmission plans, again said 2 partners that are un named are very big and want their molecule and partnership a secret for now because they are in a very competitive field and believe this could give them a leg up over competition using zsans micro needle, all sounds good but we need money
that doesn't seem probable, not if you believe the 8-k zsan released couple weeks back. pk protocol hopefully submitted to fda by end of march, fda will review and give guidance or announce changes to protocol(which is great news, seems they want this approved) then pk study would begin, once study is completed I would think results submitted back to fda if everything looks good, remember this high plasma was with only 5 patients, then fda could give us a new pudfa date, i'm hoping worst case by years end and would love it quicker, hopefully lo's presentation on 9th will shed some light
so now we have compliance and it stated 20 straight days and i'm hearing rumblings that if you asked for an additional 180 days nasdaq could then double the consecutive days from 10-20 but never found a link, Lo needs cash to not only fund cluster and new pk study but all operations so he needs to get cash in a non dilutive way, grants for covid or hopefully just 1 of 3 partners actually come forward with indication and money or if he has nothing he will do another offering, its that simple, prey for partner
I hope so, cross the fingers
So much for load and hold today...lol...I have faith the FDA approval is very near...
Thank you for your reply, i dont understand why they dont reply... what do you think is gonna happen? Any idea about the fda approval?hope to get some news..
NO, not from zsan or nasdaq, matter of fact zsan has never responded and probably sent 5-6 emails over last 2.5 years, their pr dept. for lack of a better word is crap
Did tou get news from them?
So its been over 2 weeks now of being nasdaq compliant yet still were listed as deficient, what the hell is zsan doing? wrote to their pr dept. asking for an answer, also sent one to nasdaq totaly unacceptable
Zosano Pharma has received a Notice of Allowance for its US patent application 15/882,504 titled "METHOD OF RAPIDLY ACHIEVING THERAPEUTIC CONCENTRATIONS OF TRIPTANS FOR TREATMENT OF MIGRAINES"
patentcenter.uspto.gov/#!/application…
So we are nasdaq compliant yet no official word, happened a week ago, we have 4 partners, Eversana and Mitsubishi and 2 new undisclosed partners, J&J is getting approval for their single dose vaccine and these vaccines were approved in record time for emegency use under Trumps operation warp speed, last night zsan received patent protection and also listed on patent is J&J, who Zsan was spun out of just a few years back, so while we wait for our pk study for migraine approval wouln't it be something if J&J or any of the 3 partners have been working and testing our micro needle patch with their vaccine, and perhaps we get the same emergency use approval! perhaps a long shot $$$$
So how are we doing so far? Are we going to eventually take off
Wow... yeah... really skyrocketing today. Good thing I'm long for awhile
Thanks for the Chart Video
Still shorting?
* * $ZSAN Video Chart 02-09-2021 * *
Link to Video - click here to watch the technical chart video
That’s not the whole story. ZSAN is also working on Covid 19 vaccine delivery with its patch system. ZSAN is a Johnson and Johnson spin off, and J&J just had its vaccine authorized for use in the United States. All we need here is a whiff of confirmation and this will be a $10 stock or more likely headed for $50. The virus is mutating and an easier delivery system will be needed for decades.
ZSAN " Here’s Why Zosano Pharma Is Flying
February 9, 2021 by Joshua Rodriguez "
https://cnafinance.com/zsan-stock-heres-why-zosano-pharma-is-flying/
ZSAN UP 10% Rising.. 13 X Normal Average Volume, High Relative Volume , Nearing VWAP
https://finance.yahoo.com/quote/ZSAN?p=ZSAN
TraderView Buy Rated
https://www.tradingview.com/symbols/NASDAQ-ZSAN/technicals/
http://ih.advfn.com/stock-market/NASDAQ/zosano-pharma-ZSAN/stock-price
$SNDL Out , $NXTD Watching, $Sold $ITRM too soon
$ZSAN
ZSAN volume is 58 million and it's just 10am EOM
$ZSAN is screaming for the top as Wall Street Bets Redditors work to push the shorts out of their positions as Zosano awaits an FDA approval. https://cnafinance.com/zsan-stock-heres-why-zosano-pharma-is-flying/
$ZSAN: 3.50 now in premarket....... more fire coming
Looks like $HEPA will follow suit as well.
Biggg winners here in the biospace
GO $ZSAN
****************************************************************
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta(TM) in Acute Treatment of Migraines
8:30 AM ET 2/1/21 | Dow Jones
Related Quotes
4:00 PM ET 2/8/21
Symbol Last % Chg
ZSAN
1.93 0.00%
Real time quote.
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta(TM) in Acute Treatment of Migraines
-- Review of data from the ZOTRIP trial suggest that Qtrypta showed
therapeutic gain at 30 minutes consistent with recently published
criteria for evaluating early onset of action
-- All Qtrypta patients who were pain free at 30 minutes were still pain
free at 2 hours
-- Observation of pain freedom at 30 minutes was more accurate than the
observation of relief at 30 minutes in predicting pain freedom at 2 hours
FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta(TM), Zosano's investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference.
"We believe Qtrypta shows tremendous potential to become an attractive therapeutic alternative to acutely treat migraines," said Steven Lo, President and CEO of Zosano. "As our lead program utilizing our novel microneedle patch technology designed to deliver drug through the skin, Qtrypta has demonstrated rapid pain relief in patients who are often too nauseated to take oral medications which take time to travel to the gastrointestinal tract before providing pain relief."
In a post-hoc retrospective analyses of data from the previously published ZOTRIP trial involving 365 subjects who received Qtrypta 3.8 mg or placebo, of 82 Qtrypta-treated subjects, 38 reported pain relief at 30 minutes, and 28 of the 38 subjects (74%) were pain free at two hours. All 6 subjects treated with Qtrypta who reported pain freedom at 30 minutes were pain-free at two hours. This compares to nine of 26 subjects (35%) in the placebo group (n=77) who reported pain relief at 30 minutes that were pain free at 2 hours, and 1 of 2 subjects that were pain free at 30 minutes being pain free at 2 hours.
These data describe therapeutic gain at 30 minutes, a measure consistent with recently published criteria for evaluating early onset of action published in Cephalalgia, an International Journal of Headache, by Pfelt-Hansen and Diener. The post-hoc analysis of data from the ZOTRIP trial suggests that the therapeutic gain for pain freedom, instead of pain relief, may be a more reliable endpoint for evaluating early onset of action.
"Qtrypta demonstrated rapid and robust improvement in the rates of pain relief and pain freedom in two hours. I believe that rapid onset of meaningful and sustained improvement is of utmost importance to patients suffering from migraines," said Dr. Deborah Friedman, Professor of Neurology and Ophthalmology at the University of Texas Southwestern Medical Center.
About Qtrypta(TM) (M207)
Qtrypta is Zosano's proprietary investigational formulation of zolmitriptan delivered utilizing its proprietary transdermal microneedle system (the "System") in development for the acute treatment of migraine. The System consists of titanium microneedles coated with drug, and in the case of Qtrypta(TM), the formulation is zolmitriptan. The drug-coated microneedles are designed to penetrate the stratum corneum, where the investigational drug potentially dissolves and easily enters into the bloodstream. In February 2017, the company announced statistically significant results from the ZOTRIP pivotal study, in which the 3.8 mg dose of Qtrypta(TM) met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.
About Migraine
Migraine is a highly prevalent neurological disease impacting 12% of the US population and 1 in 4 households. Patients impacted by migraine experience significant disability, with 90% unable to function normally. Migraine attacks are estimated to lead to lost productivity costs as high as $36 billion annually in the United States, including both direct and indirect costs. Zosano believes there is a significant need for new acute treatment options since 74% of migraine patients experience inadequate treatment response.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta(TM) (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential benefits of Qtrypta for patients and other future events and expectations described in this press release. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects, " "potential," "expects," "plans," "anticipates," "intends," "continues, " "forecast," "designed," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company's ability to obtain additional cash resources to continue operations, the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contacts:
Christine Matthews
Chief Financial Officer
510-745-1200
Zosano PR:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com
> Dow Jones Newswires
February 01, 2021 08:30 ET (13:30 GMT)
So a new spike today ... I Can live with that
Do u think there is a short squeeze going on?
* * $ZSAN Video Chart 02-08-2021 * *
Link to Video - click here to watch the technical chart video
This is why ZSAN is a big deal, read this and understand. This company with micro-needle technology could change healthcare industry with a micro-needle patch instead of full blown injections.
https://www.sec.gov/Archives/edgar/data/1587221/000119312521003130/d107135dex991.htm
Update 2/1/21:
https://www.sec.gov/Archives/edgar/data/1587221/000119312521023815/d118525dex991.htm
Accumulation numbers reflect institutional buying. Someone knows something. Maybe eyeing the patch technology patent and planning a buyout to obtain technology to expand to other medicines delivery using ZSAN patch technology.
There’s lots of legs left in this stock, should’ve been trading at the $2-3 range based on FDA reviews.
Whats th verdict for tomorrow? Pullback or new spike?
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1109
|
Created
|
06/25/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |